Trial Profile

Phase 1b/Phase 3 Multicenter Study Of Avelumab (msb0010718c) In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, Cd20 Antagonist And/or Conventional Chemotherapy In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (Dlbcl) Javelin Dlbcl

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 20 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Azacitidine (Primary) ; Bendamustine (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary) ; Utomilumab (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms JAVELIN DLBCL
Sponsors Pfizer

16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
20 Nov 2020 Status changed from completed to discontinued.
13 Sep 2020 This trial has been discontinued in Czech Republic , according to European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com